Journal of Pediatric and Adolescent Gynecology
Volume 20, Issue 6 , Pages 319-321 , December 2007

Genital Herpes and the Teen Female

  • Karin Batalden, MD

      Affiliations

    • Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA
    • ,
  • Corinne Bria, MD

      Affiliations

    • Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA
    • ,
  • Frank M. Biro, MD

      Affiliations

    • Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA
    • Division of Adolescent Medicine, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA
    • Corresponding Author InformationAddress correspondence to: Frank M. Biro, MD, Division of Adolescent Medicine, Cincinnati Children's Hospital Medical Center, 3333 Burnet Avenue (ML-4000), Cincinnati, OH 45229-3039

References 

  1. Xu F, Sternberg MR, Kottiri BJ, et al. Trends in herpes simplex virus type 1 and type 2 seroprevalence in the United States. JAMA. 2006;296:964
  2. Stanberry LR, Rosenthal SL, Mills L, et al. Longitudinal risk of herpes simplex virus (HSV) type 1, HSV type 2, and cytomegalovirus infections among young adolescent girls. Clin Infect Dis. 2004;39:1433
  3. Beauman JG. Genital herpes: A review. Am Fam Physician. 2005;72:1527
  4. Xu F, Schillinger JA, Sternberg MR, et al. Seroprevalence and coinfection with herpes simplex virus type 1 and type 2 in the United States, 1988–1994. J Infect Dis. 2002;185:1019
  5. CDC . Sexually Transmitted Diseases Treatment Guidelines. MMWR. 2006;2006:55;(RR11)
  6. Brown ZA, Selke S, Zeh J, et al. The acquisition of herpes simplex virus during pregnancy. N Engl J Med. 1997;337:509
  7. Carney O, Ross E, Bunker C, et al. A prospective study of the psychological impact on patients with a first episode of genital herpes. Genitourin Med. Feb 1994;70:40
  8. Taboulet F, Halioua B, Malkin JE. Quality of life and use of health care among people with genital herpes in France. Acta Derm Venereol. 1999;79:380
  9. Corey L, Wald A, Patel R, et al. Once-daily valacyclovir to reduce the risk of transmission of genital herpes. N Engl J Med. 2004;350:11
  10. Fife KH, Warren TJ, Ferrera RD, et al. Effect of valacyclovir on viral shedding in immunocompetent patients with recurrent herpes simplex virus 2 genital herpes: A US-based randomized, double-blind, placebo-controlled clinical trial. Mayo Clin Proc. 2006;81:1321
  11. Diaz-Mitoma F, Sibbald RG, Shafran SD, et al. Oral famciclovir for the suppression of recurrent genital herpes: A randomized controlled trial. Collaborative Famciclovir Genital Herpes Research Group. J Adolesc Health Care. 1998;280:887
  12. Patel R, Bodsworth NJ, Woolley P, et al. Valaciclovir for the suppression of recurrent genital HSV infection: A placebo controlled study of once daily therapy. International Valaciclovir HSV Study Group. Genitourin Med. 1997;73:105
  13. Patel R, Tyring S, Strand A, et al. Impact of suppressive antiviral therapy on the health related quality of life of patients with recurrent genital herpes infection. Sex Transm Inf. 1999;75:398
  14. Williams JR, Jordan JC, Davis EA, et al. Suppressive valacyclovir therapy: Impact on the population spread of HSV-2 infection. Sex Transm Dis. 2007;34:123
  15. Tyring SK, Baker D, Snowden W. Valacyclovir for herpes simplex virus infection: long-term safety and sustained efficacy after 20 years' experience with acyclovir. J Infect Dis. 2002;186(Suppl. 1):S40
  16. Honda M, Okuda T, Hasegawa T, et al. Effect of long-term, low-dose acyclovir suppressive therapy on susceptibility to acyclovir and frequency of acyclovir resistance of herpes simplex virus type 2. Antivir Chem Chemother. Jul 2001;12:233
  17. Aoki FY, Tyring S, Diaz-Mitoma F, et al. Single-day, patient-initiated famciclovir therapy for recurrent genital herpes: A randomized, double-blind, placebo-controlled trial. Clin Infect Dis. 2006;42:8
  18. Bodsworth NJ, Crooks RJ, Borelli S, et al. Valaciclovir versus aciclovir in patient initiated treatment of recurrent genital herpes: A randomised, double blind clinical trial. International Valaciclovir HSV Study Group. Genitourin Med. Apr 1997;73:110
  19. Chosidow O, Drouault Y, Leconte-Veyriac F, et al. Famciclovir vs. aciclovir in immunocompetent patients with recurrent genital herpes infections: a parallel-groups, randomized, double-blind clinical trial. Br J Dermatol. Apr 2001;144:818
  20. Leone PA, Trottier S, Miller JM. Valacyclovir for episodic treatment of genital herpes: A shorter 3-day treatment course compared with 5-day treatment. Clin Infect Dis. 2002;34:958
  21. Wald A, Carrell D, Remington M, et al. Two-day regimen of acyclovir for treatment of recurrent genital herpes simplex virus type 2 infection. Clin Infect Dis. 2002;34:944
  22. Sheffield JS, Hollier LM, Hill JB, et al. Acyclovir prophylaxis to prevent herpes simplex virus recurrence at delivery: A systematic review. Obstet Gynecol. 2003;102:1396
  23. Sheffield JS, Hill JB, Hollie LM, et al. Valacyclovir prophylaxis to prevent recurrent herpes at delivery: A randomized clinical trial. Obstet Gynecol. 2006;108:141

PII: S1083-3188(07)00177-5

doi: 10.1016/j.jpag.2007.04.004

Journal of Pediatric and Adolescent Gynecology
Volume 20, Issue 6 , Pages 319-321 , December 2007

Article Tools